# US 2012/0232032 A1 · Antimicrobial and/or epithelial cell growth stimulating substance and composition and tissue dressing material

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0232032 A1
- Document ID: US20120232032A1
- Status: Published application
- Kind: A1
- Application number: 13/392,673
- Filed: 2010-09-01
- Published: 2012-09-13
- Earliest claimed: 2009-09-01
- Assignees: Medovent GmbH
- Inventors: Rivelino Montenegro; Thomas Freier; Karsten Henco
- Web page: https://patentgrep.com/patent/US20120232032A1

## CPC

- A61L 26/0023: {Polysaccharides}
- A61L 15/28: Polysaccharides or their derivatives {(A61L15/225 takes precedence)}
- A61L 26/0066: {Medicaments; Biocides}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/02: Local antiseptics
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61L 2300/232: Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
- A61L 2300/404: Biocides, antimicrobial agents, antiseptic agents
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A chitosan for use in an antimicrobial treatment of a patient's tissue and a pharmaceutical composition comprising a chitosan for use in an antimicrobial treatment of a patient's tissue. A method of treating a microbial infection, the method comprising the step of administering to a patient an effective amount of a chitosan and an aqueous solution comprising chitosan. A chitosan or a pharmaceutical composition comprising a chitosan for use in an epithelial cell growth stimulating treatment of a patient's tissue. A method of stimulating the growth of epithelial cells the method comprising the step of administering to a patient or to an epithelial cells containing cell culture an effective amount of a chitosan or a pharmaceutical composition comprising chitosan. A tissue dressing material characterized in that it consists of chitosan or a chitosan comprising composition.

## Claims

### Claim 1

A method for treating a microbial infection, preventing the risk of a microbial infection, reducing the microbial load of an existing microbial infection, or preventing or reducing the spread of a microbial infection, with methicillin-resistant Staphylococcus aureus (MRSA) infection, oxacillin-resistant Staphylococcus aureus (ORSA) infection, multidrug-resistant Clostridium difficile infection, penicillin-resistant Streptococcus pneumonia infection, multidrug-resistant Pseudomonas aeruginosa infection, or multidrug-resistant Acinetobacter baumannii infection, the method comprising:
administering to a patient an effective amount of a native chitosan or a pharmaceutical composition comprising native chitosan.

### Claim 2 (depends on 1)

The chitosan method according to claim 1, wherein
the treatment is locally confined.

### Claim 3 (depends on 1)

The chitosan method according to claim 1, wherein
the chitosan's degree of acetylation is 40% or less.

### Claim 4 (depends on 3)

The method according to claim 3, wherein
the chitosan is deacetylated.

### Claim 5 (depends on 3)

The method according to claim 3, wherein
the chitosan is preparable by a method that comprises at least two deacetylation steps.

### Claim 6 (depends on 1)

The method according to claim 1, wherein
a fraction of more than 10% of the chitosan is present in a form that is insoluble at a pH of 6.5 or greater.

### Claim 7 (depends on 1)

The method according to claim 1, wherein
a fraction of more than 1% of the chitosan is present in a form that is soluble at a pH of 6.5.

### Claim 8 (depends on 1)

The method according to claim 1, wherein
a fraction of more than 10% of the chitosan has a molecular weight of 10 kD or more.

### Claim 9 (depends on 1)

The method according to claim 1, wherein
a fraction of more than 0.1% of the chitosan has a molecular weight of less than 10 kD.

### Claim 10

A pharmaceutical composition for for treating a patient's tissue for at least one of the following or a combination thereof: preventing the risk of a microbial infection, reducing the microbial load of an existing microbial infection, preventing or reducing the spread of a microbial infection, the infection is at least one of the following or a combination thereof: methicillin-resistant Staphylococcus aureus (MRSA) infection, oxacillin-resistant Staphylococcus aureus (ORSA) infection, multidrug-resistant Clostridium difficile infection, penicillin-resistant Streptococcus pneumonia infection, multidrug-resistant Pseudomonas aeruginosa infection, multidrug-resistant Acinetobacter baumannii infection, the pharmaceutical composition comprising a native chitosan.

### Claim 11 (depends on 10)

The pharmaceutical composition according to claim 10, wherein
the pharmaceutical composition is free of alcohol.

### Claim 12 (depends on 10)

The pharmaceutical composition according to claim 10, wherein
the pharmaceutical composition is a liquid.

### Claim 13 (depends on 12)

The pharmaceutical composition according to claim 12, wherein
the pharmaceutical composition is an aqueous solution of chitosan.

### Claim 14 (depends on 10)

The pharmaceutical composition according to claim 10, wherein
the pharmaceutical composition is solid or gel-like.

### Claim 15 (depends on 10)

The pharmaceutical composition according to claim 10, wherein
the treatment is locally confined.

### Claim at position 16

16-18. (canceled)

### Claim 19

A method of stimulating the growth of epithelial cells the method comprising: administering to a patient or to an epithelial cells containing cell culture an effective amount of native chitosan or a pharmaceutical composition comprising native chitosan.

### Claim 20 (depends on 20)

The method of claim 20, wherein
the epithelial cells are keratinocytes.

### Claim 21

A method of preparing chitosan for use in an antimicrobial treatment of a patient's tissue or in an epithelial cell growth stimulating treatment, wherein
the chitosan is deacetylated in at least two deacetylation steps.

### Claim 22

A tissue dressing material consisting of chitosan with a degree of acetylation of 20% or less, wherein
a fraction of more than 10% of the chitosan has a molecular weight of 10 kD or more and a fraction of more than 0.1% of the chitosan has a molecular weight of less than 10 kD.

### Claim 23 (depends on 22)

The tissue dressing material of claim 22, wherein
the chitosan is native chitosan.

### Claim 24 (depends on 23)

The tissue dressing material according to claim 23, wherein
the chitosan is deacetylated.

### Claim 25 (depends on 22)

The tissue dressing material according to claim 22, wherein
the chitosan is preparable by a method that comprises at least two deacetylation steps.

### Claim 26 (depends on 22)

The tissue dressing material according to claim 22, wherein
a fraction of more than 10% of the chitosan is present in a form that is insoluble at a pH of 6.5 or greater.

### Claim 27 (depends on 22)

The tissue dressing material according to claim 22, wherein
a fraction of more than 1% of the chitosan is present in a form that is soluble at a pH of 6.5.

### Claim 28

A tissue dressing material being a composition comprising chitosan with a degree of acetylation of 20% or less, wherein
a fraction of more than 10% of the chitosan has a molecular weight of 10 kD or more and
a fraction of more than 0.1% of the chitosan has a molecular weight of less than 10 kD.

### Claim 29 (depends on 28)

The tissue dressing material according to claim 28, wherein
the chitosan containing composition is free of alcohol or any other organic solubilizer or stabilizer.

### Claim 30 (depends on 28)

The tissue dressing material according to claim 28, wherein
the chitosan containing composition is a liquid.

### Claim 31 (depends on 30)

The tissue dressing material according to claim 30, wherein
the chitosan containing composition is an aqueous solution of chitosan.

### Claim 32 (depends on 28)

The tissue dressing material according to claim 28, wherein
the chitosan containing composition is solid or gel-like.

### Claim 33

An aqueous solution comprising chitosan with a degree of acetylation of 20% or less, wherein
a fraction of more than 10% of the chitosan has a molecular weight of 10 kD or more and
a fraction of more than 0.1% of the chitosan has a molecular weight of less than 10 kD.

### Claim 34 (depends on 10)

The pharmaceutical composition of claim 10 wherein the chitosan's degree of acetylation is 40% or less or wherein the chitosan is deacetylated.

### Claim 35 (depends on 10)

The pharmaceutical composition of claim 10 wherein the chitosan is preparable by a method that comprises at least two deacetylation steps.

### Claim 36 (depends on 10)

The pharmaceutical composition of claim 10 wherein a fraction of more than 10% of the chitosan is present in a form that is insoluble at a pH of 6.5 or greater or wherein a fraction of more than 1% of the chitosan is present in a form that is soluble at a pH of 6.5.

### Claim 37 (depends on 10)

The pharmaceutical composition of claim 10 wherein a fraction of more than 10% of the chitosan has a molecular weight of 10 kD or more or wherein a fraction of more than 0.1% of the chitosan has a molecular weight of less than 10 kD.
